Sunitinib induced nephrotic syndrome and thrombotic microangiopathy

Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor of targets such as vascular endothelial growth factor and platelet derived growth factor receptor. It is used for the treatment of metastatic renal cell carcinoma (RCC). Use of sunitinib has been associated with renal dysfunction...

Full description

Bibliographic Details
Main Authors: P K Jha, M Vankalakunti, V Siddini, R Bonu, G K Prakash, K Babu, H S Ballal
Format: Article
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Indian Journal of Nephrology
Online Access:;year=2013;volume=23;issue=1;spage=67;epage=70;aulast=Jha